FIGURE 49. Deterministic base-case incremental cost–utility for ImR CML: cost–utility plane.

FIGURE 49Deterministic base-case incremental cost–utility for ImR CML: cost–utility plane

C-E, cost-effectiveness.

From: Appendix 8, Cost-effectiveness in imatinib-resistant chronic myeloid leukaemia in chronic phase (including interferon)

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.